Safety and Efficacy Study of rAAV2-ND4 Treatment of Leber Hereditary Optic Neuropathy (LHON)

计划入组 9 人 · 首次发布于 2010 年 12 月 28 日

A Single Intravitreal Injection of rAAV2-ND4 for the Treatment of Leber's Hereditary Optic Neuropathy

计划入组 159 人 · 首次发布于 2017 年 5 月 15 日

Efficacy Study of Gene Therapy for The Treatment of Acute LHON Onset Within Three Months

计划入组 120 人 · 首次发布于 2018 年 2 月 9 日

AAV2 smCBA based ND4 gene therapy (University of Miami)

AAV2 smCBA based G11778A ND4 gene therapy (University of Miami)

Ndc Inc

United States

NDO Surgical, Inc.

United States

GenSight Biologics Secures French Regulatory Approvals for GS010/LUMEVOQ Gene Therapy in Rare Blindness Disease

GenSight Biologics Secures FDA Authorization for Expanded Access Treatment of Rare Blinding Disease

LUMEVOQ Gene Therapy Shows Sustained Vision Improvement in LHON Patients After 5 Years